(NASDAQ: SNDX) Syndax Pharmaceuticals's forecast annual revenue growth rate of 38.72% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.9%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Syndax Pharmaceuticals's revenue in 2026 is $252,251,000.On average, 15 Wall Street analysts forecast SNDX's revenue for 2026 to be $31,303,986,468, with the lowest SNDX revenue forecast at $26,122,076,568, and the highest SNDX revenue forecast at $35,562,564,500. On average, 14 Wall Street analysts forecast SNDX's revenue for 2027 to be $44,276,174,151, with the lowest SNDX revenue forecast at $35,494,698,714, and the highest SNDX revenue forecast at $57,810,040,506.
In 2028, SNDX is forecast to generate $60,752,379,489 in revenue, with the lowest revenue forecast at $45,724,572,886 and the highest revenue forecast at $79,211,873,107.